A5090677971- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Biochemical and Molecular Research
- Protein Degradation and Inhibitors
- Folate and B Vitamins Research
- Insect Resistance and Genetics
- RNA modifications and cancer
- Monoclonal and Polyclonal Antibodies Research
- Viral Infectious Diseases and Gene Expression in Insects
- Chronic Myeloid Leukemia Treatments
- Biosimilars and Bioanalytical Methods
- Epigenetics and DNA Methylation
- Polyamine Metabolism and Applications
- Peptidase Inhibition and Analysis
- Ovarian function and disorders
- Historical and Linguistic Studies
- Reproductive Biology and Fertility
- Beetle Biology and Toxicology Studies
- Archaeology and Historical Studies
- Ubiquitin and proteasome pathways
- Cancer-related gene regulation
- Spectroscopy and Laser Applications
- Historical Astronomy and Related Studies
- Immunodeficiency and Autoimmune Disorders
Memorial Sloan Kettering Cancer Center
2022-2025
Kettering University
2024
Massey University
2024
University of Illinois Chicago
2023
Albert Einstein College of Medicine
2016-2021
Icahn School of Medicine at Mount Sinai
2020
Mount Sinai Hospital
2011-2013
Lunenfeld-Tanenbaum Research Institute
2011-2013
University of Toronto
2011-2013
Wesleyan University
2010
Abstract B-cell maturation antigen (BCMA)–targeting therapeutics have dramatically improved outcomes in relapsed/refractory multiple myeloma (RRMM). However, whether the mechanisms of resistance between these therapies are shared and how identification such before therapy initiation could refine clinical decision-making remains undefined. We analyzed for 72 RRMM patients treated with teclistamab, a CD3 × BCMA bispecific antibody, 42% (30/72) whom had prior BCMA-directed exposure. Malignant...
Teclistamab, a B-cell maturation antigen (BCMA)- and CD3-targeting bispecific antibody, is an effective novel treatment for relapsed/refractory multiple myeloma (R/RMM), but efficacy in patients exposed to BCMA-directed therapies mechanisms of resistance have yet be fully delineated. We conducted real-world retrospective study commercial teclistamab, capturing both clinical outcomes immune correlates response cohort (n = 52) with advanced R/RMM. Teclistamab was highly overall rate (ORR) 64%,...
ABSTRACT: The objective of this study was to determine the effects low‐level laser light exposure on motility spermatozoa and DNA damage. Thirty‐three semen samples were collected for routine analysis classified as normospermic, oligospermic, or asthenospermic. After performed, residual divided into treated control aliquots. Treated exposed a 30‐second infrared pulse 50 mW/cm 2 at 905 nm, wavelength thought increase light‐sensitive cytochrome c oxidase in mitochondrial electron transport...
Current prognostic scores in multiple myeloma (MM) currently rely on disease burden and a limited set of genomic alterations. Some studies have suggested gene expression panels may predict clinical outcomes, but none are presently utilized practice. The tyrosine kinase WEE1 is critical cell cycle regulator during the S-phase G2M checkpoint. Abnormal has been implicated cancers including breast, ovarian, gastric cancers, its signal MM not thoroughly reported. We, therefore, analyzed MMRF...
Abstract Teclistamab (Tec) is a first-in-class BCMA × CD3 bispecific T-cell engager antibody approved for treating multiple myeloma progressing after at least 4 lines of therapy. The objective this study was to evaluate the rate cytokine release syndrome (CRS) in patients who were treated with commercial Tec and had prior exposure other redirection therapies. A retrospective chart review performed identify completed step-up dosing phase between November 2022 2023. Patients divided into 2...
8049 Background: Teclistamab (Tec) is the first CD3 x BCMA bispecific antibody (BsAb) receiving accelerated FDA approval for treatment of relapsed or refractory multiple myeloma (RRMM) in patients who have received ≥4 prior lines therapy, including a PI, IMiD and an anti-CD38 monoclonal antibody. The was based on results MajesTec-1 study (Usmani S et al Lancet 2021, Moreau P NEJM 2022), demonstrating 63% overall response rate heavily pretreated RRMM population. Patients with exposure to...
The aim of this study was to explore associations between habitual dietary fibre intake, adiposity, and biomarkers metabolic health in Pacific New Zealand European women who are known have different disease risks. (n = 126) (NZ European; n 161) (18-45years) were recruited the PROMISE cross-sectional (1) based on normal (18-24.9kg/m2) obese BMI (≥30kg/m2). Body fat percentage (BF%), measured using whole body DXA, used stratify participants into low (<35%) or high (≥35%) BF% groups....
MCARH109 is a first-in-class G protein–coupled receptor, class C, group 5, member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma. This phase I clinical trial included 17 and determined that safe at maximum tolerated dose of 150 × 10 6 CAR T cells. In this updated analysis, no new serious adverse events were reported median follow-up 37 months. Overall, 12 (71%) responded, including seven (70%) previously treated...
Human 5'-methylthioadenosine phosphorylase (MTAP) catalyzes the phosphorolysis of (MTA). Its action regulates cellular MTA and links polyamine synthesis to S-adenosylmethionine (AdoMet) salvage. Transition state analogues with picomolar dissociation constants bind MTAP in an entropically driven process at physiological temperatures, suggesting increased hydrophobic character or dynamic structure for complexes. Inhibitor binding exhibits a negative heat capacity change (-ΔCp), thus changes...
The Fourier transform microwave spectra of the various isotopologs weakly bound complex carbon dioxide with most abundant molecule in atmosphere, nitrogen, have been measured. structure has determined and evidence for inversion N(2) is presented. T-shaped, OCO forming cross T, a consistent that deduced from previous rotationally resolved infrared experiment. A significant wide-amplitude bending motion values (nearly identical) nuclear quadrupole coupling constants nitrogen nuclei....
Human methionine S-adenosyltransferase (MAT2A) catalyzes the formation of S-adenosylmethionine (SAM) from ATP and methionine. Synthetic lethal genetic analysis has identified MAT2A as an anticancer target in tumor cells lacking expression 5'-methylthioadenosine phosphorylase (MTAP). Approximately 15% human cancers are MTAP-/-. The remainder can be rendered MTAP- through MTAP inhibitors. We used kinetic isotope effect (KIE), commitment factor (Cf), binding (BIE) measurements combined with...
Plasmodium falciparum parasites are purine auxotrophs that rely exclusively on the salvage of preformed purines from their human hosts to supply requirement for nucleotides. Hypoxanthine-guanine-xanthine phosphoribosyltransferase (HGXPRT) catalyzes freely reversible Mg2+-dependent conversion 6-oxopurine bases respective nucleotides and inorganic pyrophosphate. The phosphoribosyl group is derived 5-phospho-α-d-ribosyl 1-pyrophosphate (PRPP). enzyme malaria (PfHGXPRT) essential as hypoxanthine...
Bacterial 5'-methylthioadenosine/ S-adenosylhomocysteine nucleosidase (MTAN) hydrolyzes adenine from its substrates to form S-methyl-5-thioribose and S-ribosyl-l-homocysteine. MTANs are involved in quorum sensing, menaquinone synthesis, 5'-methylthioadenosine recycling S-adenosylmethionine. Helicobacter pylori uses MTAN unusual pathway, making H. a target for antibiotic development. Human phosphorylase (MTAP), reported anticancer target, catalyzes phosphorolysis of salvage Transition-state...
5'-Methylthioadenosine phosphorylase (MTAP) and 5'-methylthioadenosine nucleosidase (MTAN) catalyze the phosphorolysis hydrolysis of (MTA), respectively. Both enzymes have low K
A mouse model of human Familial Adenomatous Polyposis responds favorably to pharmacological inhibition 5'-methylthioadenosine phosphorylase (MTAP). Methylthio-DADMe-Immucillin-A (MTDIA) is an orally available, transition state analogue inhibitor MTAP. 5'-Methylthioadenosine (MTA), the substrate for MTAP, formed in polyamine synthesis and recycled by MTAP S-adenosyl-L-methionine (SAM) via salvage pathways. MTDIA treatment causes accumulation MTA, which inhibits growth head neck (FaDu) lung...
When stimulating a patient with poor ovarian response for IVF, the maximal dose of gonadotropins injected is often determined by arbitrary standards rather than measured response. The purpose this study was to determine if serum FSH concentration during an IVF stimulation cycle reflects follicular utilization and whether values may inform adjustments exogenous FSH. In retrospective cross sectional we studied 155 consecutive cycles stimulated only recombinant human We included long GnRH...